164 related articles for article (PubMed ID: 1790395)
1. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis.
Muff R; Dambacher MA; Fischer JA
Osteoporos Int; 1991 Feb; 1(2):72-5. PubMed ID: 1790395
[TBL] [Abstract][Full Text] [Related]
2. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease.
Levy F; Muff R; Dotti-Sigrist S; Dambacher MA; Fischer JA
J Clin Endocrinol Metab; 1988 Sep; 67(3):541-5. PubMed ID: 3410939
[TBL] [Abstract][Full Text] [Related]
3. In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin.
Grauer A; Raue F; Schneider HG; Frank-Raue K; Ziegler R
J Bone Miner Res; 1990 Apr; 5(4):387-91. PubMed ID: 2343778
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intranasal human calcitonin in patients with Paget's disease refractory to salmon calcitonin.
Muff R; Dambacher MA; Perrenoud A; Simon C; Fischer JA
Am J Med; 1990 Aug; 89(2):181-4. PubMed ID: 2382666
[TBL] [Abstract][Full Text] [Related]
5. Formation of neutralizing antibodies after treatment with human calcitonin.
Grauer A; Reinel HH; Lunghall S; Lindh E; Ziegler R; Raue F
Am J Med; 1993 Oct; 95(4):439-42. PubMed ID: 8213878
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of antibodies against calcitonin.
Grauer A; Ziegler R; Raue F
Exp Clin Endocrinol Diabetes; 1995; 103(6):345-51. PubMed ID: 8788305
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibodies against calcitonin.
Grauer A; Reinel HH; Ziegler R; Raue F
Horm Metab Res; 1993 Sep; 25(9):486-8. PubMed ID: 8225203
[TBL] [Abstract][Full Text] [Related]
8. Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.
Reginster JY; Gaspar S; Deroisy R; Zegels B; Franchimont P
Osteoporos Int; 1993 Sep; 3(5):261-4. PubMed ID: 8400608
[TBL] [Abstract][Full Text] [Related]
9. Functional significance of antibody formation after long-term salmon calcitonin therapy.
Hosking DJ; Denton LB; Cadge B; Martin TJ
Clin Endocrinol (Oxf); 1979 Mar; 10(3):243-52. PubMed ID: 572275
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
11. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study.
Pontiroli AE; Pajetta E; Scaglia L; Rubinacci A; Resmini G; Arrigoni M; Pozza G
Aging (Milano); 1994 Dec; 6(6):459-63. PubMed ID: 7748920
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide.
Evans RA; Somers NM; Dunstan CR; Hills E; Evans M
Calcif Tissue Int; 1991 Sep; 49(3):164-7. PubMed ID: 1933580
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin resistance: clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonins.
Haddad JG; Caldwell JG
J Clin Invest; 1972 Dec; 51(12):3133-41. PubMed ID: 4674398
[TBL] [Abstract][Full Text] [Related]
14. Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study.
Pontiroli AE; Pajetta E; Calderara A; Alberetto M; Pozza G; Manganelli V; Resmini G; Tessari L; Maresca V
J Endocrinol Invest; 1991 Jan; 14(1):47-51. PubMed ID: 1646250
[TBL] [Abstract][Full Text] [Related]
15. [Neutralizing antibodies against salmon calcitonin. The cause of a treatment failure in Paget's disease].
Grauer A; Frank-Raue K; Schroth J; Raue F; Ziegler R
Dtsch Med Wochenschr; 1994 Apr; 119(14):507-10. PubMed ID: 8156882
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget's disease.
González D; Vega E; Ghiringhelli G; Mautalen C
Calcif Tissue Int; 1987 Dec; 41(6):313-5. PubMed ID: 3124939
[TBL] [Abstract][Full Text] [Related]
17. Paget's disease of the bone: observations after cessation of long-term synthetic salmon calcitonin treatment.
Avramides A; Flores A; DeRose J; Wallach S
J Clin Endocrinol Metab; 1976 Mar; 42(3):459-63. PubMed ID: 1254686
[TBL] [Abstract][Full Text] [Related]
18. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
Thamsborg G; Jensen JE; Kollerup G; Hauge EM; Melsen F; Sorensen OH
Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
[TBL] [Abstract][Full Text] [Related]
19. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
Gennari C; Agnusdei D; Montagnani M; Gonnelli S; Civitelli R
Calcif Tissue Int; 1992 Apr; 50(4):381-3. PubMed ID: 1571851
[TBL] [Abstract][Full Text] [Related]
20. Calcitonins: newer routes of delivery.
Reginster JY
Osteoporos Int; 1993; 3 Suppl 2():S3-6; discussion S6-7. PubMed ID: 8481597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
